MyLeukemiaTeam

That's an exciting development to be following! Here's what is known about zanubrutinib (also called Brukinsa) in the context of leukemia treatment in the U.S.

Zanubrutinib is FDA-approved for treating adults with chronic lymphocytic leukemia (CLL). It belongs to a class of drugs called kinase inhibitors, and it works by Show Full Answer

That's an exciting development to be following! Here's what is known about zanubrutinib (also called Brukinsa) in the context of leukemia treatment in the U.S.

Zanubrutinib is FDA-approved for treating adults with chronic lymphocytic leukemia (CLL). It belongs to a class of drugs called kinase inhibitors, and it works by blocking a protein in cancer cells called Bruton's tyrosine kinase (BTK), which helps stop leukemia cells from growing and spreading. Regarding the combination of zanubrutinib with sonrotoclax specifically, this pairing is still being studied in clinical trials. As of now, this exact combination does not appear to have full FDA approval in the U.S. — it's more likely still in the trial phase there too.

It's worth noting that:
- Phase 3 trials are a very advanced and promising stage of drug research
- Drugs must show their benefits outweigh risks before full approval is granted
- Trial availability can vary by country and site

It would be worth speaking directly with your oncologist or hematologist about whether this trial in Austria could be an option for you, as eligibility criteria can be very specific.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Treatments

Brukinsa